07:00 , Mar 24, 2014 |  BioCentury  |  Emerging Company Profile

Bullet: Idiotype builder

Bullet Biotechnology Inc. is using new sequencing and manufacturing methods to develop an idiotype cancer vaccine that it anticipates will be more effective than first-generation products. President and CEO Willie Quinn said the first wave...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Aragen Bioscience, GVK Biosciences deal

GVK Biosciences will acquire fellow CRO Aragen. GVK said the deal gives the company Aragen's expertise in biologic services and a significant U.S. presence. The companies did not disclose financial details. Aragen Bioscience Inc. ,...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Aragen Bioscience, Xoma Ltd. sales and marketing update

Xoma granted Aragen rights to make Xoma's Human Engineering technology to humanize antibodies discovered in mice to Aragen clients. Aragen provides cell line development and preclinical production services. Terms were not disclosed. Aragen Bioscience Inc....
07:00 , Jun 7, 2010 |  BC Week In Review  |  Company News

Amorfix, Aragen Bioscience deal

Aragen will generate mAbs against disease-specific epitopes on misfolded Fas receptor (CD95) identified by Amorfix to treat cancer. Amorfix will have exclusive, worldwide rights to the mAbs. Further terms were not disclosed. Amorfix Life Sciences...
07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Aragen Bioscience, Cevec deal

Aragen received a non-exclusive, worldwide license to use Cevec's CAP-T expression technology and human CAP cell line to produce glycosylated human proteins in serum-free cultures. Cevec will receive an undisclosed upfront payment and yearly maintenance...